Compare CFND & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CFND | ANL |
|---|---|---|
| Founded | N/A | 2004 |
| Country | | Cayman Islands |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 350.9M |
| IPO Year | 2025 | 2022 |
| Metric | CFND | ANL |
|---|---|---|
| Price | $3.91 | $8.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 24.8K | ★ 218.7K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.68 | $0.88 |
| 52 Week High | $9.67 | $12.09 |
| Indicator | CFND | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 56.84 |
| Support Level | $3.75 | $1.37 |
| Resistance Level | $4.08 | $10.15 |
| Average True Range (ATR) | 0.17 | 0.94 |
| MACD | 0.04 | -0.29 |
| Stochastic Oscillator | 62.00 | 60.20 |
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.